Accepted papers:

• Riviere MK, Dubois F, Zohar S. Competing designs for drug combination in phase I dose-finding clinical trials, Stat Med 2015, 34(1):1-12.
• Riviere MK, Dubois F, Zohar S. Response to ‘Comments on Competing designs for drug combination in phase I dose-finding clinical trials’ by G. Yin, R. Lin and N. Wages, Stat Med 2015, 34(1):23-6.
• Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model, Pharm Stat 2014, 13(4):247-57.
• Riviere MK, Zohar S. Comments on ‘A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies’, Stat Med 2015, 35(3):475-478.
• Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian Dose-finding Design for Clinical Trials Combining a Cytotoxic Agent with a Molecularly Targeted Agent, JRSS-C 2015, 64(1):215–229.
• Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature, Annals of Oncology 2014, 26(4):669-674.
• Riviere MK, Jourdan JH, Zohar S. dfcomb: An R-package for phase I/II trials of drug combinations, in press in Computer Methods and Programs in Biomedicine.
• Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II Dose-Finding Design for Molecularly Targeted Agent: Plateau Determination using Adaptive Randomization, in press in Statistical Methods in Medical Research.
• Riviere MK, Ueckert S, Mentré F. An MCMC-method for the evaluation of the Fisher information matrix in nonlinear mixed effect model, in minor revision in Biostatistics.
• Simon Y, Marchadier A, Riviere MK, Vandamme K, Trouve A, Koenig F, Lezot F, Benhamou CL, Saffar JL , Berdal A , Nefussi JR. Cephalometric assessment of craniofacial dysmorphologies in relation with Msx2 mutations in mouse, Orthod Craniofac Res 2014, 17(2):92-105.